Results 11 to 20 of about 273,364 (223)

A Discrete Simulation Optimization Approach Towards Calibration of an Agent-based Simulation Model of Hepatitis C Virus Transmission [PDF]

, 2021
This study demonstrates the implementation of the stochastic ruler discrete simulation optimization method for calibrating an agent-based model (ABM) developed to simulate hepatitis C virus (HCV) transmission. The ABM simulates HCV transmission between agents interacting in multiple environments relevant for HCV transmission in the Indian context.
arxiv   +1 more source

Sox4 represses host innate immunity to facilitate pathogen infection by hijacking the TLR signaling networks

Virulence, 2021
Toll-like receptors (TLRs) are essential for the protection of the host from pathogen infections by initiating the integration of contextual cues to regulate inflammation and immunity.
Jian Shang, Yuan Zheng, Jiayin Mo, Wenbiao Wang, Zhen Luo, Yongkui Li, Xulin Chen, Qiwei Zhang, Kailang Wu, Weiyong Liu, Jianguo Wu   +10 more
doaj   +1 more source

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

New England Journal of Medicine, 2015
BACKGROUND A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need.
J. Feld, I. Jacobson, C. Hézode, T. Asselah, P. Ruane, N. Gruener, A. Abergel, A. Mangia, Ching‐lung Lai, H. L. Chan, F. Mazzotta, Christophe Moreno, E. Yoshida, S. Shafran, W. Towner, T. Tran, J. McNally, A. Osinusi, E. Svarovskaia, Yanni Zhu, D. Brainard, J. Mchutchison, K. Agarwal, S. Zeuzem   +23 more
semanticscholar   +1 more source

Treatment of HCV infection by targeting microRNA.

New England Journal of Medicine, 2013
BACKGROUND The stability and propagation of hepatitis C virus (HCV) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 (miR-122).
H. Janssen, H. Reesink, E. Lawitz, S. Zeuzem, M. Rodríguez-Torres, K. Patel, A. J. van der Meer, A. Patick, Alice Chen, Yi Zhou, R. Persson, B. King, S. Kauppinen, A. Levin, M. Hodges   +14 more
semanticscholar   +1 more source

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

New England Journal of Medicine, 2014
BACKGROUND In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with ...
N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin, M. Puoti, M. Romero‐Gomez, J. Zarski, K. Agarwal, P. Buggisch, G. Foster, N. Bräu, M. Buti, I. Jacobson, G. Subramanian, Xiao Ding, H. Mo, Jenny C. Yang, P. Pang, W. Symonds, J. Mchutchison, A. Muir, A. Mangia, P. Marcellin   +23 more
semanticscholar   +1 more source

Comparative study on anti-HCV testing using plasma, dried plasma spots (DPS), and dried blood spots (DBS)Highlights

Biosafety and Health, 2021
The aim of this study was to evaluate the performance of an assay using dried plasma spot (DPS) and dried blood spot (DBS) samples for the serological detection of anti-hepatitis C virus (HCV) antibodies.
Jieqiong Ma, Lin He, Kai Chen, Yuehua Wang, Yanan Ren, Wenge Xing, Yan Jiang   +6 more
doaj  

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

New England Journal of Medicine, 2017
BACKGROUND Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct‐acting antiviral agents (DAAs) have limited retreatment options.
H. Ford, M. Bourliere, S. Gordon, S. Flamm, C. Cooper, A. Ramji, M. Tong, N. Ravendhran, J. Vierling, T. Tran, S. Pianko, M. Bansal, V. Ledinghen, R. Hyland, L. Stamm, H. Dvory‐Sobol, E. Svarovskaia, Jie Zhang, K. C. Huang, G. Subramanian, D. Brainard, J. Mchutchison, E. Verna, P. Buggisch, C. Landis, Z. Younes, M. Curry, S. Strasser, E. Schiff, K. Reddy, M. Manns, K. Kowdley, S. Zeuzem   +32 more
semanticscholar   +1 more source

The Immunohistochemical Staining of Vimentin and E-Cadherin in Bladder Cancer Patients Infected with Hepatitis C Virus

Journal of Pure and Applied Microbiology, 2023
The invasion and spread of cancer cells are two of the most notable characteristics of malignant tumors. Recent studies suggest that the epithelial-mesenchymal transition (EMT) has been linked to this significant occurrence.
May K. Ismael, Yasir B. Qaddoori, Mustafa N. Shaban, Bahaa Abdullah Laftaah AL-Rubaii   +3 more
doaj   +1 more source

FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest

Hepatology, 2007
To optimize the management of patients with chronic hepatitis C virus (HCV) infection, noninvasive tests to determine the degree of hepatic fibrosis have been developed.
A. Vallet-Pichard, V. Mallet, B. Nalpas, V. Verkarre, A. Nalpas, V. Dhalluin-Venier, H. Fontaine, S. Pol   +7 more
semanticscholar   +1 more source

Reduction of Liver Fibrosis After Treatment with Elbasvir/Grazoprevir in Patients with Hepatitis C Infection in Chronic Kidney Disease on Hemodialysis, a Quasi-Experimental Study

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 2021
Background: Approximately 5-60% of hemodialysis patients have comorbid of hepatitis C virus (HCV) infection. The survival rate of hemodialysis patients HCV is lower than those without HCV due to the risk of liver fibrosis and cardiovascular disease.
Bayu Laksono, Nenny Agustanti, Rudi Supriyadi, Muhammad Begawan Bestari, Siti Aminah Abdurachman   +4 more
doaj   +1 more source